BioElectronics Announces Publication of Electroceuticals Article on Chronic Pain

FREDERICK, MD, Oct. 04, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC Pink: BIEL), the maker of non-invasive electroceutical devices, announced the publication of an article in the October 2018 edition of the European Biopharmaceutical Review. Titled “Effective Electroceuticals,” the article provides insights into how electroceuticals (devices that provide electrical therapy) are set to revolutionize chronic pain management in the 21st century.

Chronic pain is a highly prevalent condition that affects more than 100 million Americans. Central sensitization (a.k.a. nerve hypersensitivity) is often seen as the physiological explanation for chronic pain. Existing pharmacotherapy options such as topicals, NSAID’s and opioids offer limited relief and present serious side effects with long-term use. Electroceutical devices can target central sensitization and are ideal for treating pain, but existing options (TENS etc.) require invasive or semi-invasive use and produce uncomfortable sensations. ActiPatch®, made by BioElectronics, is the only electroceutical that is non-invasive (no skin contact needed), can be used 24/7 and does not provide any uncomfortable sensations.

The article was authored by Dr. Kenneth McLeod, Ph.D., Director of the Clinical Science and Engineering Research Laboratory at the State University of New York, Binghamton and Dr. Sree Koneru, Ph.D., VP of Product Development at BioElectronics Corporation. The original article can be viewed at: article .

About BioElectronics Corporation: BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit

Paul Knopick